NEW YORK (GenomeWeb) – New data from a clinical study funded by the breast cancer charity Side-Out Foundation indicates the ability of multi-omic analyses to improve the effectiveness of therapy in patients with metastatic disease.
According to Emanuel Petricoin, co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University and one of the leaders of the study, initial results from the second Side-Out study suggest that using molecular data to guide patient treatment extends progression-free survival in metastatic breast cancer patients.
This is in line with results from the first Side-Out study, which found that in 13 of 25 subjects therapies selected using genomic and proteomic analyses of patient tumors extended progression-free survival by more than 30 percent compared to the patient’s last treatment regimen.
That finding was notable, Petricoin said, in that typical progression-free survival decreases as patients move through treatment options.
“What we reported in the first trial is actually more than half the patients had… an increase in progression-free survival,” he said, adding that while he and his colleagues are still completing analysis of data from the second Side-Out study, the results appear to be “in keeping with” those from the first study.